TScan Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
TCRX$0.18-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $128,057 | $152,406 |
| Prepaid expenses and other current assets | 4,709 | 4,802 |
| Total current assets | 132,766 | 157,208 |
| Property and equipment, net | 8,120 | 8,706 |
| Right-of-use assets | 56,006 | 57,743 |
| Restricted cash | 5,031 | 5,031 |
| Long-term deposit and other assets | 68 | 101 |
| Total assets | $201,991 | $228,789 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,303 | $1,241 |
| Accrued expenses and other current liabilities | 8,592 | 7,668 |
| Operating lease liability, current portion | 7,438 | 7,167 |
| Deferred revenue, current portion | 1,637 | 2,619 |
| Total current liabilities | 19,970 | 18,695 |
| Operating lease liability, net of current portion | 52,445 | 54,437 |
| Long-term debt and accrued interest | 32,654 | 32,534 |
| Total liabilities | 105,069 | 105,666 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | - | - |
| Voting common stock, $0.0001 par value; 300,000,000 shares authorized; 55,824,722 and 52,625,035 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 6 | 5 |
| Non-voting common stock, $0.0001 par value; 10,000,000 shares authorized; 4,276,588 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 1 | 1 |
| Additional paid-in capital | 630,443 | 627,979 |
| Accumulated other comprehensive loss | - | - |
| Accumulated deficit | (533,528) | (504,862) |
| Total stockholders' equity | 96,922 | 123,123 |
| Total liabilities and stockholders' equity | $201,991 | $228,789 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.